Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.

2.

Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.

Mo ES, Cheng Q, Reshetnyak AV, Schlessinger J, Nicoli S.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12027-12032. doi: 10.1073/pnas.1710254114. Epub 2017 Oct 23.

3.

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.

Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4784-93. doi: 10.1073/pnas.1610179113. Epub 2016 Aug 1.

4.

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.

Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16.

5.

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J.

Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916.

PMID:
25605972
6.

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.

Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J.

Mol Cell. 2015 Jan 8;57(1):191-201. doi: 10.1016/j.molcel.2014.11.021. Epub 2014 Dec 24.

7.

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.

Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J.

Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17832-7. doi: 10.1073/pnas.1317118110. Epub 2013 Oct 14.

8.

Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics.

Smirnov I, Carletti E, Kurkova I, Nachon F, Nicolet Y, Mitkevich VA, Débat H, Avalle B, Belogurov AA Jr, Kuznetsov N, Reshetnyak A, Masson P, Tonevitsky AG, Ponomarenko N, Makarov AA, Friboulet A, Tramontano A, Gabibov A.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15954-9. doi: 10.1073/pnas.1108460108. Epub 2011 Sep 6.

9.

Active state of sensory rhodopsin II: structural determinants for signal transfer and proton pumping.

Gushchin I, Reshetnyak A, Borshchevskiy V, Ishchenko A, Round E, Grudinin S, Engelhard M, Büldt G, Gordeliy V.

J Mol Biol. 2011 Sep 30;412(4):591-600. doi: 10.1016/j.jmb.2011.07.022. Epub 2011 Aug 4.

PMID:
21840321
10.

Antibodies-antidotes against organophosphorus compounds.

Kurkova IN, Reshetnyak AV, Durova OM, Knorre VD, Tramontano A, Friboulet A, Ponomarenko NA, Gabibov AG, Smirnov IV.

Dokl Biochem Biophys. 2009 Mar-Apr;425:94-7. No abstract available.

PMID:
19496331
11.

Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice.

Durova OM, Vorobiev II, Smirnov IV, Reshetnyak AV, Telegin GB, Shamborant OG, Orlova NA, Genkin DD, Bacon A, Ponomarenko NA, Friboulet A, Gabibov AG.

Mol Immunol. 2009 Nov;47(1):87-95. doi: 10.1016/j.molimm.2008.12.020. Epub 2009 Feb 6.

PMID:
19201029
12.

Routes to covalent catalysis by reactive selection for nascent protein nucleophiles.

Reshetnyak AV, Armentano MF, Ponomarenko NA, Vizzuso D, Durova OM, Ziganshin R, Serebryakova M, Govorun V, Gololobov G, Morse HC 3rd, Friboulet A, Makker SP, Gabibov AG, Tramontano A.

J Am Chem Soc. 2007 Dec 26;129(51):16175-82. Epub 2007 Nov 29.

13.

Mechanism-dependent selection of immunoglobulin gene library for obtaining covalent biocatalysts.

Reshetnyak AV, Armentano MF, Morse HC, Friboulet A, Makker SP, Tramontano A, Knorre VD, Gabibov AG, Ponomarenko NA.

Dokl Biochem Biophys. 2007 Jul-Aug;415:179-82. No abstract available.

PMID:
17933329
14.

Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120.

Ponomarenko NA, Vorobiev II, Alexandrova ES, Reshetnyak AV, Telegin GB, Khaidukov SV, Avalle B, Karavanov A, Morse HC 3rd, Thomas D, Friboulet A, Gabibov AG.

Biochemistry. 2006 Jan 10;45(1):324-30.

PMID:
16388609
15.

Catalytic transformations of supercoiled DNA as studied by flow linear dichroism technique.

Gabibov A, Yakubovskaya E, Lukin M, Favorov P, Reshetnyak A, Monastyrsky M.

FEBS J. 2005 Dec;272(24):6336-43.

16.

DNA polymerase iota-like activity in crude cell extracts of different mouse organs.

Gening LV, Petrochenkov AN, Reshetnyak AB, Andreeva LE, Tarantul VZ.

Biochemistry (Mosc). 2004 Apr;69(4):435-40. Erratum in: Biochemistry (Mosc). 2009 Jan;74(1):114.

PMID:
15170381
17.

Study of the dynamics of supercoiled DNA.

Yakubovskaya EA, Lukin MA, Reshetnyak AV, Gabibov AG, Monastyrskii MI.

Dokl Biochem Biophys. 2003 May-Jun;390:184-8. No abstract available.

PMID:
12959075
18.

Antibody proteases: induction of catalytic response.

Gabibov AG, Friboulet A, Thomas D, Demin AV, Ponomarenko NA, Vorobiev II, Pillet D, Paon M, Alexandrova ES, Telegin GB, Reshetnyak AV, Grigorieva OV, Gnuchev NV, Malishkin KA, Genkin DD.

Biochemistry (Mosc). 2002 Oct;67(10):1168-79.

19.

Kinetics of interactions between DNA and topoisomerase II in the presence of physiologically active effectors.

Favorov PV, Yakubovskaya EA, Reshetnyak AV, Gabibov AG.

Dokl Biochem. 2000 Jan-Feb;370(1-6):38-41. No abstract available.

PMID:
11977249

Supplemental Content

Loading ...
Support Center